enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages

Key Points

• Analyst sentiment is mixed: Fourteen firms give enGene an average “Hold” rating, with 8 holds, 3 buys, 1 strong buy and 2 sells. Their average 12-month price target is $11.05.
• Shares opened at $1.68, near the 52-week low of $1.40 and well below the 52-week high of $12.25. enGene also reported a quarterly loss of $0.47 per share, missing analysts’ $0.43 loss estimate.
• Institutional investors own 64.16% of the stock; several funds increased their positions, including Siren L.L.C., which raised its stake by 57.5%.

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned an average recommendation of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, eight have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $11.05.

A number of research firms have recently issued reports on ENGN. Citizens Jmp restated a "market perform" rating on shares of enGene in a report on Wednesday, September 9th. Weiss Ratings downgraded enGene from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 30th. HC Wainwright reissued a "buy" rating on shares of enGene in a research report on Friday, October 16th. Jefferies Financial Group raised shares of enGene to a "strong-buy" rating in a report on Tuesday, October 13th. Finally, Wall Street Zen raised shares of enGene from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th.

Key enGene News

Here are the key news stories impacting enGene this week:

• Neutral Sentiment: Several stories discuss using engines to power AI data centers, including potential water savings and repurposed jet engines. These developments do not directly relate to enGene. Engine-powered data centers challenge combined-cycle turbines with 99% water savings Retired jet engines finding second life powering AI data centers
• Neutral Sentiment: Other articles cover new rocket and drone engines, as well as automotive engine topics; none describe enGene’s business or prospects. 3D-printed Northstar booster engine packs 715,000 pounds of thrust US Army successfully flies a hybrid electric drone

Hedge Funds Weigh In On enGene

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SR One Capital Management LP bought a new position in shares of enGene during the second quarter worth approximately $1,293,607. Eversept Partners LP grew its stake in enGene by 12.0% during the first quarter. Eversept Partners LP now owns 510,543 shares of the company's stock worth $3,477,000 after buying an additional 54,708 shares in the last quarter. Renaissance Technologies LLC increased its stake in enGene by 651.1% in the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company's stock valued at $1,063,000 after acquiring an additional 135,318 shares during the last quarter. Siren L.L.C. lifted its position in shares of enGene by 57.5% during the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company's stock worth $35,774,000 after buying an additional 1,916,895 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in enGene during the first quarter worth about $409,000. 64.16% of the stock is owned by institutional investors.

enGene Stock Down 2.3%

Shares of enGene stock opened at $1.68 on Friday. The business has a 50-day moving average price of $1.78 and a 200 day moving average price of $4.23. enGene has a fifty-two week low of $1.40 and a fifty-two week high of $12.25. The firm has a market cap of $112.59 million, a P/E ratio of -0.81 and a beta of -0.24. The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, sell-side analysts forecast that enGene will post -1.82 earnings per share for the current fiscal year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.